5 research outputs found
Clinical and economic outcomes of risperidone versus clozapine in the treatment of chronic schizophrenia
Background: The purpose of this study was to examine clinical outcomes and direct cost associated with risperidone and clozapine for the treatment of chronic schizophrenia.Methods: In a prospective observational study on 100 patients with schizophrenia in a tertiary care setting clinical outcome was measured using positive and negative syndrome scale (PANSS) and costs by direct medical cost.Results: Both risperidone and clozapine significantly reduced the severity of psychotic symptoms (scores on the PANSS) from baseline, with no significant between group differences. The clinical improvement was more in the case of clozapine compared to risperidone group (p=0.479). In both groups, extrapyramidal symptoms and other adverse events were few, and their severity was generally mild. A statistical significance was noted in the total direct cost which was higher in patients receiving clozapine when compared to risperidone.Conclusions: Risperidone was well tolerated and as effective as clozapine in patients with chronic schizophrenia and more economical than clozapine
Adverse drug reaction to antiparkinson agents in Idiopathic Parkinson Disease: a prospective observational study in a Movement Disorder outpatient clinic
Background: Parkinson disease (PD) generally requires therapy for prolonged periods often with multiple drugs; drug-related adverse effects often add to the existing morbidity. Although, such ADRs are common, comprehensive information about their incidence, severity, and ultimate health effects are not available. The objective of the study was to analyze the pattern of occurrence of Adverse Drug Reactions (ADRs) in patients receiving anti-parkinson agents (APA) in a tertiary care hospital. We also aimed to assess the causality, severity and preventability of these ADRs.Methods: This prospective, observational study with 6 month follow up was conducted among consecutive PD patients receiving anti parkinson agents attending the Movement disorder clinic of Neurology department between April 1st 2011 and September 30th 2012. Tools used were ADR Reporting form of National Pharmacovigilance centre, WHO causality scale, Hartwig and Siegel scale to assess severity and Schumock and Thornton scale to assess preventability of ADRs. Descriptive statistics was used and the values were expressed in numbers and percentages.Results: ADRs were experienced in 87 patients (82.1%) out of 106 patients and most of these patients were on combination therapy (66%). No gender difference in distribution of ADRs was observed. The most common reactions were sedation, dizziness, dry mouth and fatigue. The drug usage was in the order of pramipexole (58.4%), levodopa+carbidopa (55.7%), trihexyphenidyl (28.3%), entacapone (5.7%) and amantadine (7.5%). Majority of the ADRs were mild level 1 (71.1%). ADR was maximum with entacapone. Majority of ADRs belonged to the causality possible ADR category. All the ADRs came under the definitely or probably preventable category.Conclusions: ADRs with antiparkinsonian drugs is common but mild and preventable
Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
Objectives: The tolerability and efficacy of lanthanum carbonate has
not been studied in the Indian population. This study was, therefore,
undertaken to compare the efficacy and tolerability of lanthanum
carbonate with calcium acetate in patients with stage 4 chronic kidney
disease. Design: A randomized open label two group cross-over study.
Materials and Methods: Following Institutional Ethics Committee
approval and valid consent, patients with stage 4 chronic kidney
disease were randomized to receive either lanthanum carbonate 500 mg
thrice daily or calcium acetate 667 mg thrice daily for 4 weeks. After
a 4-week washout period, the patients were crossed over for another 4
weeks. Serum phosphorous, serum calcium, serum alkaline phosphatase,
and serum creatinine were estimated at fixed intervals. Results:
Twenty-six patients were enrolled in the study. The mean serum
phosphorous concentrations showed a declining trend with lanthanum
carbonate (from pre-drug levels of 7.88 ± 1.52 mg/dL-7.14 ±
1.51 mg/dL) and calcium acetate (from pre-drug levels of 7.54 ±
1.39 mg/dL-6.51 ± 1.38 mg/dL). A statistically significant
difference was seen when comparing the change in serum calcium produced
by these drugs (P < 0.05). Serum calcium levels increased with
calcium acetate (from pre-drug levels of 7.01 ± 1.07-7.46 ±
0.74 mg dL), while it decreased with lanthanum carbonate (from pre-drug
levels 7.43 ± 0.77-7.14 ± 0.72 mg/ dL). The incidence of
adverse effects was greater with lanthanum carbonate. Conclusion:
Lanthanum carbonate and calcium acetate are equally effective phosphate
binders with trends obvious in the first 4 weeks of therapy. The
decrease in serum calcium levels with lanthanum carbonate when compared
to the increase in serum calcium levels due to calcium acetate is
statistically significant. The drawback of lanthanum carbonate is its
high cost and relatively higher incidence of adverse events during
treatment
Calcium channel blockers- Induced iatrogenic gingival hyperplasia: Case series
Hypertension rightfully termed as “Silent killer” is associated with increase in morbidity and mortality when left untreated. Calcium channel blockers are the most commonly prescribed first-line anti-hypertensive drugs in India. Calcium channel blockers are known to cause gingival hyperplasia but with lower incidence rates compared to the other two groups causing iatrogenic gingival overgrowth, immunosuppressants, and anticonvulsants. Nifedipine administration, among the calcium channel blockers, has been frequently associated with iatrogenic gingival hyperplasia. Incidence of amlodipine-induced gingival hyperplasia which has similar pharmacodynamic action like nifedipine, had been reported rarely. Here, we present a case series of drug induced gingival overgrowth caused by calcium channel blockers used for the management of hypertension. All the patient's condition improved after withdrawal of the offending drug, oral prophylaxis and intervention, and alternate drug from other first-line drugs were started for managing hypertension